ATNM Actinium Pharmaceuticals, Inc
XASE 1.40 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ATNM
$1.40
—
Key stats
$1.40
Pre-market
$1.44
+3.01%
- 52-Week Range
- $0.74 – $1.72
- YTD
- +2.19%
- Straddle Price
- $1.07
- P/C Vol Ratio
- 1.67
- Market Cap
- $0.0B
- Open
- $1.50
- Day Range
- $1.36 – $1.53
- Volume
- 205,864
- Prev Close
- $1.52
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.05 |
| Cost of Equity (CAPM) | 10.75% (VRP-adj) |
| WACC | 10.96% |
| Volatility Risk Premium | +327.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 37.3% |
| Book / Price | 5.3% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -25830.0% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $1.16 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.20 |
| Bollinger Width / SMA20 | 4765.5% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
33%
20-Day Fair Value
≈ by Nov 25, 2026
$1.42
α +1.3%
rank 55%
conviction
71%
40-Day Fair Value
≈ by Dec 24, 2026
$1.42
α +1.6%
rank 60%
conviction
52%
60-Day Fair Value
≈ by Jan 22, 2027
$1.41
α +0.9%
rank 45%
conviction
33%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $0.26 | 5% | median 3.5× · 3 peers |
| Peer P/S | $0.01 | 17% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $1.16 | 78% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XASE
- Market Cap
- $0.0B
- Employees
- 25
- List Date
- 2007-07-19
- CIK
- 0001388320
- Next Earnings
- 2026-11-13
- EPS Forecast
- ($0.25) (2 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.actiniumpharma.com
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT fo…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.25% | -15.47% | 16.97% | 1.13% | -7.94% | -15.33% | -3.40% |
| Feb | -2.77% | -0.37% | -16.74% | 53.42% | -2.54% | -3.28% | 4.62% |
| Mar | -5.46% | -4.13% | -8.87% | -7.56% | 51.89% | -12.69% | 2.20% |
| Apr | -4.96% | 16.57% | -4.35% | -10.05% | 2.01% | 12.12% | 1.89% |
| May | 5.97% | -8.76% | -9.29% | 4.76% | 3.36% | 11.50% | 1.26% |
| Jun | -8.34% | -12.55% | -11.03% | -9.20% | -13.58% | -16.95% | -11.94% |
| Jul | -13.95% | -0.60% | -3.39% | -3.89% | 20.74% | -15.08% | -2.70% |
| Aug | -12.01% | 46.15% | -15.83% | -69.94% | 10.56% | 25.69% | -2.56% |
| Sep | 45.96% | -0.94% | -10.98% | 0.53% | -7.51% | 12.51% | 6.59% |
| Oct | -8.51% | 83.22% | -0.36% | -1.10% | -10.63% | 21.74%* | 14.06% |
| Nov | -13.82% | -16.45% | -15.50% | -15.79% | 0.00% | -- | -12.31% |
| Dec | -12.39% | -1.93% | 0.79% | -10.64% | -0.73% | -- | -4.98% |
| Total | -35.06% | 62.24% | -57.91% | -73.47% | 36.02% | 8.53% | -9.94% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.20
SMA 50: $1.16
SMA 200: $1.12
Current: $1.40
EMA 12: $1.32
EMA 26: $1.23
MACD: 0.0848 | Signal: 0.0421
BULLISH
ADX (14): 28.73
TREND
+DI: 37.77
−DI: 16.94
Momentum Oscillators
RSI (14): 59.69
NEUTRAL
Stoch %K: 78.40
Stoch %D: 81.86
Williams %R: -36.62
Volume & Volatility
BB Upper: $1.54
BB Lower: $0.86
NEUTRAL
OBV: 10,678,726
Vol SMA 20: 248,967
Vol ROC: 108.97%
ATR: $0.12
True Range: $0.17
HV 20: 106.3%
HV 30: 88.8%
HV 60: 90.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: ATNM
Executive Summary
- Overall Assessment: NEUTRAL (confidence level: 6/10)
- Key Drivers and Primary Risks:
- Positive market sentiment and news headlines on targeted alpha therapies
- Low volatility, indicating a relatively stable stock price movement
- Negative recent news headlines on legal issues and potential class-action lawsuits
- 2-3 Sentence Investment Thesis: ATNM's stock performance is influenced by the positive outlook on targeted alpha therapies, which may drive long-term growth. However, the recent negative news headlines on legal issues could impact short-term sentiment. Investors should monitor the situation closely to adjust their investment strategy accordingly.
- Recent News Sentiment Impact: The recent news headlines have a mixed impact on ATNM's stock price movement. Positive news on targeted alpha therapies may drive short-term gains, while negative news on legal issues could lead to a short-term pullback.
Technical Analysis
- Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BULLISH
- Long-term (3-12 months): BULLISH
- Support/Resistance Levels: The stock is currently trading above the SMA 20 and EMA 12, indicating a strong uptrend. Resistance levels are at $1.22, while support levels are at $0.95.
- Momentum Signals:
- RSI (14): Overbought (>70)
- MACD: Bullish signal
- Bollinger Bands: Overbought
- Volume Analysis: The volume is increasing, indicating growing institutional interest and potential buying pressure.
News & Sentiment Analysis
- Recent Headlines Summary: Recent news headlines have been mixed, with positive news on targeted alpha therapies and negative news on legal issues.
- Sentiment Assessment: Aggregated sentiment is NEUTRAL, with both positive and negative news headlines contributing to the overall assessment.
- Catalyst Identification: The catalyst for ATNM's stock price movement is the positive outlook on targeted alpha therapies, which may drive long-term growth. However, the recent negative news headlines on legal issues could impact short-term sentiment.
- Market Narrative: The market narrative suggests that ATNM's stock performance is influenced by both fundamental and technical factors. Positive news on targeted alpha therapies may drive long-term gains, while negative news on legal issues could lead to a short-term pullback.
Risk & Volatility Assessment
- Beta Interpretation: Beta is low (0.71), indicating less volatility than the broader market.
- Volatility Regime: The current volatility level is relatively low compared to historical levels.
- Options Market Signals:
- IV Rank: Medium
- Put/Call Volume Ratio: Neutral
- Downside Protection: Support levels are at $0.95, and investors may consider using stop-loss orders or adjusting their risk management strategy accordingly.
Market Context & Positioning
- Sector Performance: ATNM's sector (healthcare) is performing relatively well compared to the broader market.
- Institutional Activity: Institutional interest is growing, as indicated by increasing volume.
- Correlation Analysis: The stock has a low correlation with the broader market (R-squared = 0.13), indicating less volatility.
- Relative Valuation: ATNM's relative valuation suggests that it may be slightly undervalued compared to its peers.
Key Levels & Action Items
- Critical Price Levels: Resistance levels are at $1.22, and support levels are at $0.95.
- Breakout/Breakdown Levels: A breakout above $1.22 could lead to further gains, while a breakdown below $0.95 could indicate a pullback.
- Time-Sensitive Catalysts: The catalyst for ATNM's stock price movement is the positive outlook on targeted alpha therapies and potential class-action lawsuits.
- Risk Management: Investors may consider using stop-loss orders or adjusting their risk management strategy accordingly, given the recent negative news headlines.
Additional Comments
- Flag: No flag raised due to data quality or unusual technical readings.
- Note: The market narrative suggests that ATNM's stock performance is influenced by both fundamental and technical factors. Positive news on targeted alpha therapies may drive long-term gains, while negative news on legal issues could lead to a short-term pullback.
Conclusion
ATNM's stock price movement is influenced by the positive outlook on targeted alpha therapies and potential class-action lawsuits. The recent negative news headlines on legal issues have impacted short-term sentiment, but investors should monitor the situation closely to adjust their investment strategy accordingly. With low volatility and a relatively stable stock price movement, ATNM may be a suitable investment for those looking for long-term growth opportunities.
Generated
News
All ATNM news →
ATNM Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.07
7-DTE Move: $1.07
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 9
Put Volume: 15
P/C Volume: 1.667
BEARISH
Call OI: 1,709
Put OI: 0
P/C OI: —
Total OI: 1,709
ATM Options Pricing
ATM Call: $0.05
ATM Put: $1.02
Call %: 3.6%
Put %: 73.2%
Chain Summary
Chain Volume: 161
Chain OI: 3,983
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 35th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
35%
vs own history
GEX tilt
+0.04
OI-weighted, today
Vanna tilt
+0.12
δ-sensitivity to IV
Charm tilt
-0.17
δ-decay vs time
? What is this?
· 5 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 508.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.07Oct 26
Beta Analysis
Risk Metrics
Beta: 0.3677
Alpha: 2.95%
Correlation: 0.0644
R-Squared: 0.4%
Stock Volatility: 72.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ATNM
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $504K | #3166 of 3716 | -8.9% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $373K | #2712 of 3138 | -19.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $4K | #4300 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ATNM Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 31,206,338 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$25.28K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $19.11K | 75.58% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $3.63K | 14.34% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $2.55K | 10.08% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
ATNM Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Matthew T David | Chief Financial Officer | Award (A) | +250,000 | — | EDGAR | |
| 2026-09-04 | Sandesh Seth | Chief Executive Officer | Award (A) | +1,780,874 | — | EDGAR | |
| 2026-09-04 | Richard I Steinhart | Director | Award (A) | +62,800 | — | EDGAR | |
| 2026-09-04 | June Sherie Almenoff | Director | Award (A) | +18,000 | — | EDGAR | |
| 2026-09-04 | Jeffrey W. Chell | Director | Award (A) | +61,600 | — | EDGAR | |
| 2026-09-04 | Ajit Shetty | Director | Award (A) | +61,600 | — | EDGAR | |
| 2026-09-04 | C. David Nicholson | Director | Award (A) | +62,800 | — | EDGAR | |
| 2025-08-20 | Sandesh Seth | Chief Executive Officer | Tax (F) | −120,900 | $1.71 | -$206.7K | EDGAR |
| 2025-04-02 | June Sherie Almenoff | Director | Disp (D) | −50,000 opt | — | EDGAR | |
| 2025-04-02 | Ajit Shetty | Director | Disp (D) | −182,484 opt | — | EDGAR | |
| 2025-04-02 | Richard I Steinhart | Director | Disp (D) | −184,984 opt | — | EDGAR | |
| 2025-04-02 | Jeffrey W. Chell | Director | Disp (D) | −182,484 opt | — | EDGAR | |
| 2025-04-02 | Sandesh Seth | Chief Executive Officer | Disp (D) | −2,385,976 opt | — | EDGAR | |
| 2025-04-02 | C. David Nicholson | Director | Disp (D) | −184,984 opt | — | EDGAR | |
| 2025-04-02 | Steve O'Loughlin | Chief Financial Officer | Disp (D) | −706,588 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ATNM Insider Holdings
8 insiders · @ $1.40
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Sandesh Seth | Chief Executive Officer | 938,081 | $1.31M | $87.1K | 22 | 2026-09-04 |
| 2 | Matthew T David | Chief Financial Officer | 250,000 | $350.0K | $0 | 1 | 2026-10-16 |
| 3 | C. David Nicholson | Director | 63,300 | $88.6K | $10.0K | 10 | 2026-09-04 |
| 4 | Richard I Steinhart | Director | 63,116 | $88.4K | $5.0K | 12 | 2026-09-04 |
| 5 | Ajit Shetty | Director | 62,357 | $87.3K | $9.8K | 9 | 2026-09-04 |
| 6 | Jeffrey W. Chell | Director | 61,600 | $86.2K | $0 | 8 | 2026-09-04 |
| 7 | June Sherie Almenoff | Director | 18,000 | $25.2K | $0 | 3 | 2026-09-04 |
| 8 | Steve O'Loughlin | Chief Financial Officer | 1,183 | $1.7K | $14.4K | 11 | 2025-04-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ATNM Board & Officers
As of SEC filings through Oct 16, 2026Directors 6
- C. David Nicholson · since Dec 28, 2012
- Sandesh Seth · since Dec 28, 2012
- Richard I Steinhart · since Nov 8, 2013
- Ajit Shetty · since Mar 28, 2017
- Jeffrey W. Chell · since Apr 27, 2018
- June Sherie Almenoff · since Nov 1, 2024
Officers 4
- Sandesh Seth · Chief Executive Officer · listed since Jul 2019
- Matthew T David · Chief Financial Officer · since Oct 14, 2026
- Adeela Kamal · Chief Scientific Officer · since Sep 3, 2026
- Steffen Wilhem Heeger · Chief Medical Officer · since Sep 3, 2026
Changes in the last 10 years (18)
| Oct 14, 2026 | Matthew T David became Chief Financial Officer |
| Sep 3, 2026 | Steffen Wilhem Heeger became Chief Medical Officer |
| Sep 3, 2026 | Adeela Kamal became Chief Scientific Officer |
| Nov 1, 2024 | June Sherie Almenoff became a director |
| Dec 29, 2023 | Steve O'Loughlin no longer listed as a director in SEC filings |
| Jul 1, 2022 | Steve O'Loughlin first listed as a director in an SEC filing |
| Aug 14, 2020 | Steve O'Loughlin listed as Chief Financial Officer (previously Principal Financial Officer) in SEC filings |
| Jul 16, 2019 | Sandesh Seth listed as Chief Executive Officer (previously Chairman & CEO) in SEC filings |
| Apr 27, 2018 | Jeffrey W. Chell became a director |
| Mar 8, 2018 | Nitya G. Ray listed as Executive VP (previously Executive Vice President) in SEC filings |
| Feb 6, 2018 | Anil Kapur became Chief Commercial Officer |
| Jan 8, 2018 | Dale L. Ludwig became Chief Scientific Officer |
| Jun 15, 2017 | Steve O'Loughlin listed as Principal Financial Officer (previously VP, Finance and Corporate Dev.) in SEC filings |
| Jun 15, 2017 | Sandesh Seth listed as Chairman & CEO (previously Executive Chairman) in SEC filings |
| Jun 15, 2017 | Nitya G. Ray became Executive Vice President |
| May 15, 2017 | Steve O'Loughlin became VP, Finance and Corporate Dev. |
| Mar 28, 2017 | Ajit Shetty became a director |
| Mar 16, 2017 | Mark Stanley Berger became Chief Medical Officer |
Not reported recently (8)
- Steve O'Loughlin · Last reported as Chief Financial Officer in an SEC filing dated Apr 2, 2025
- Mark Stanley Berger · Last reported as Chief Medical Officer in an SEC filing dated Sep 3, 2021
- Dale L. Ludwig · Last reported as Chief Scientific Officer in an SEC filing dated Aug 14, 2020
- Anil Kapur · Last reported as Chief Commercial Officer in an SEC filing dated Jul 16, 2019
- Nitya G. Ray · Last reported as Executive VP in an SEC filing dated Jul 17, 2018
- Dragan Cicic · Last reported as COO and Chief Medical Officer in an SEC filing dated Mar 16, 2017
- Sergio Traversa · Last reported as a director in an SEC filing dated Mar 16, 2017
- Kaushik J Dave · Last reported as a director in an SEC filing dated Mar 16, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold ATNM
3 shown · $1.53M total exposure · 0.01% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.75
TTM Revenue
$90.00K
TTM Net Income
$-23.47M
TTM Op. Cash Flow
$-22.88M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-5.52M | $-0.18 | $-5.87M |
| Q4 '25 | 2025-12-31 | $0.00 | $-5.94M | $-0.19 | $-5.29M |
| Q3 '25 | 2025-09-30 | $90.00K | $-5.13M | $-0.16 | $-6.33M |
| Q2 '25 | 2025-06-30 | — | $-6.88M | $-0.22 | $-5.39M |
| Q1 '25 | 2025-03-31 | — | $-15.94M | $-0.51 | $-7.57M |
| Q4 '24 | 2024-12-31 | — | $-6.65M | $-0.21 | $-5.75M |
| Q3 '24 | 2024-09-30 | — | $-11.57M | $-0.37 | $-11.97M |
| Q2 '24 | 2024-06-30 | — | $-11.35M | $-0.38 | $-7.97M |
| Q1 '24 | 2024-03-31 | — | $-8.67M | $-0.31 | $-7.37M |
| Q4 '23 | 2023-12-31 | $81.00K | $-9.32M | $-0.33 | $-7.49M |
| Q3 '23 | 2023-09-30 | — | $-13.28M | $-0.49 | $-11.12M |
| Q2 '23 | 2023-06-30 | — | $-15.18M | $-0.58 | $-13.64M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-08
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
18.96
P/S
485.43
EV/EBITDA
—
EV/Sales
17.30
ROE
-1018.7%
ROA
-51.7%
Div Yield
0.00%
FCF Yield
-52.36%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$43.69M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
705.86K
SI % of Float
2.26%
Days to Cover
8.68
Short Vol Ratio
15.3%
Free Float
31.26M
Float %
99.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-13